English
Specials
    Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsBusinessCOVID-19 Vaccine | Sputnik V debuts on CoWIN, available in Hyderabad for Rs 1,250

    COVID-19 Vaccine | Sputnik V debuts on CoWIN, available in Hyderabad for Rs 1,250

    The vaccine is now an available option at Apollo Hospital in Hyderabad for those aged above 45

    Moneycontrol News
    May 18, 2021 / 13:42 IST
    India approved the Sputnik V COVID-19 vaccine for emergency use on April 13. (Representative image: Sputnik V)

    Sputnik V, the Russian COVID-19 vaccine being produced in India by Dr Reddy's Laboratory has made its debut on the CoWIN platform on May 18.

    As of time of publishing, the vaccine is only available at Apollo Hospital in Hyderabad for Rs 1,250 per jab for those aged 45 and above.

    A screenshot of the Sputnik V vaccine available for booking on CoWIN at Apollo Hospital, Hyderabad A screenshot of the CoWIN app shows Sputnik V jabs fully booked at Apollo Hospital, Hyderabad

    Follow our LIVE Updates on the coronavirus pandemic here

    Dr Reddy's on May 17 said that eight to nine states – including Andhra Pradesh and Telangana have approached it for procurement of Sputnik V.

    COVID-19 Vaccine

    Frequently Asked Questions

    View more
    How does a vaccine work?

    A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

    How many types of vaccines are there?

    There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

    What does it take to develop a vaccine of this kind?

    Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

    View more
    Show

    Related stories

    It also announced a partnership with Apollo Hospitals for a trial rollout of the Sputnik V COVID-19 vaccine, wherein Dr Reddy's will use the services of the Apollo Hospitals network nationally in storage, transportation, administering and monitoring of people who get vaccinated.

    Apollo Hospitals had then said it will be pricing the jab at Rs 1,200- Rs 1,250 per dose.

    Dr Reddy's had also said that the initial rollout will begin in Hyderabad and will be extended to Visakhapatnam and other metro cities.

    Earlier, Dr Reddy's had announced that imported doses of Russia's Sputnik V COVID-19 vaccine will be priced at Rs 948 plus 5 percent GST or Rs 995.40 per dose. It said the price of the imported Sputnik V vaccine would remain the same for the government and private channels.

    Dr Reddy's has received 1.5 lakh doses of Sputnik first dose last week, the company said it has received the second consignment of 60,000 doses second dose during the weekend.

    Besides Apollo Hospital, Dr Reddy's has also tied up with IHH Healthcare’s Continental Hospitals.

    When Russian Direct Investment Fund (RDIF) and Gamaleya Institute's Sputnik V was granted approval for emergency use in India, it became the third vaccine and first foreign option – besides Serum Institute’s Covishield and Bharat Biotech Covaxin, in the country’s vaccination drive.

    The timing of its entry is crucial as India has opened up its vaccination drive for all citizens above the age of 18 from May 1.

    Follow our full COVID-19 coverage here

    Moneycontrol News
    first published: May 18, 2021 12:33 pm

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Subscribe to Tech Newsletters

    • On Saturdays

      Find the best of Al News in one place, specially curated for you every weekend.

    • Daily-Weekdays

      Stay on top of the latest tech trends and biggest startup news.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347